Scarica l'app Stockscreener
2.76
9.52%
0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.52
Aprire:
$2.55
Volume 24 ore:
1.98M
Relative Volume:
0.83
Capitalizzazione di mercato:
$248.18M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-0.9583
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+7.39%
1M Prestazione:
+6.15%
6M Prestazione:
+34.63%
1 anno Prestazione:
-20.92%
Intervallo 1D:
$2.49
$2.76
Intervallo di 1 settimana:
$2.39
$2.76
Portata 52W:
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Confronta EDIT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.76 | 226.60M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Brokers Offer Predictions for Editas Medicine Q3 Earnings - MarketBeat
Editas Medicine Bets On Next-Gen Gene Editing - Finimize
Statistical indicators supporting Editas Medicine Inc.’s strengthRate Hike & AI Driven Stock Reports - Newser
Using portfolio simulators with Editas Medicine Inc. includedJuly 2025 Sector Moves & Growth Focused Entry Reports - Newser
What drives Editas Medicine Inc.’s stock price2025 Top Gainers & Capital Efficient Trading Techniques - خودرو بانک
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Outlook & High Return Stock Watch Alerts - خودرو بانک
Can Editas Medicine Inc. weather a recession2025 Year in Review & Verified Technical Signals - خودرو بانک
Is Editas Medicine Inc. a momentum stockJuly 2025 Recap & Accurate Intraday Trade Tips - خودرو بانک
Can Editas Medicine Inc. expand into new marketsWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Predicting Editas Medicine Inc. trend using moving averages2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - Newser
Volatility Watch: Is Editas Medicine Inc. stock influenced by commodity prices2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Wells Fargo & Company Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - MarketBeat
Is Editas Medicine Inc. forming a bottoming baseQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating - AInvest
Using Ichimoku Cloud for Editas Medicine Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Editas Medicine Inc. stock ready for a breakoutJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Real time scanner hits for Editas Medicine Inc. explainedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
How to escape a deep drawdown in Editas Medicine Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.10 Consensus Target Price from Analysts - MarketBeat
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience - Investing.com
Can volume confirm reversal in Editas Medicine Inc.Quarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Is Editas Medicine Inc. stock entering bullish territoryPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Recession Risk & AI Forecast Swing Trade Picks - Newser
Is Editas Medicine Inc. showing signs of accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Evaluating Editas Medicine Inc. with trendline analysisQuarterly Profit Summary & Consistent Growth Stock Picks - Newser
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $4 to $4 - 富途牛牛
Editas Medicine price target raised to $4 from $3 at Wells Fargo - TipRanks
Editas Medicine at Wells Fargo Conference: Gene Editing Milestone - Investing.com
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - خودرو بانک
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - خودرو بانک
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Yahoo Finance
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Can Editas Medicine Inc. grow without external fundingJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - خودرو بانک
Editas Medicine’s Strategic Milestone in In Vivo Gene Editing: A Catalyst for Long-Term Value - AInvest
Chart based exit strategy for Editas Medicine Inc.Swing Trade & Reliable Trade Execution Plans - Newser
Macro Review: Is Editas Medicine Inc.’s ROE strong enoughWeekly Profit Report & Growth Oriented Trading Recommendations - خودرو بانک
Applying big data sentiment scoring on Editas Medicine Inc.Earnings Beat & Intraday High Probability Alerts - Newser
Does Editas Medicine Inc. stock have upside surprise potentialTrade Performance Summary & Daily Growth Stock Investment Tips - خودرو بانک
When is the best time to exit Editas Medicine Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Editas Medicine shares rise 1.30% after-hours after unveiling lead development candidate EDIT-401. - AInvest
Editas Medicine shares fall 1.75% intraday after announcing EDIT-401 as lead in vivo development candidate. - AInvest
What the charts say about Editas Medicine Inc. today2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
Editas turns to cholesterol therapy, becoming latest gene editing company to pivot to more common diseases - Endpoints News
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):